Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Merck
Colorcon
Moodys
Boehringer Ingelheim

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

SYNAGIS Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for SYNAGIS

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AbbViePhase 3
The University of Texas Health Science Center, HoustonN/A
AbbVie (prior sponsor, Abbott)Phase 3

See all SYNAGIS clinical trials

Recent Litigation for SYNAGIS

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
PIECZENIK v. BAYER CORPORATION2010-05-04

See all SYNAGIS litigation

Pharmacology for SYNAGIS
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionFusion Protein Inhibitors

Patent Text Search: US Patents for SYNAGIS

These patents were identified by searching patent claims

Supplementary Protection Certificates for SYNAGIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
300753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
92780 Luxembourg   Start Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
300822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
CR 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
PA2016022 Lithuania   Start Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Medtronic
Mallinckrodt
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.